Clinical usefulness of eosinopenia in differentiating COVID-19 versus other flu-like illness in outpatient set-up
Keywords:COVID, Eosinopenia, Lymphopenia, flu-like illnesses
Introduction and Aim:Corona virus disease 2019 (Covid-19) is a highly infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has affected over 200 countries and territories. The aim of the present study is to evaluate the role of eosinopenia in differentiating COVID-19 suspect from other flu-like illnesses in an outpatient setting.
Materials and Methods:It was a retrospective case control study in which data of 1252 suspected COVID 19 patients who visited the fever clinic were enrolled. Among this, 701 patients were found to have COVID-19 pneumonia and 551 had other flu-like illnesses. CBC (complete blood count) and CRP(C- reactive protein) were taken in all patients along with chest x-ray as routine protocol.
Results:Among the 701 positive patients, eosinopenia was seen in 527 patients and had a sensitivity of 75.2 % and specificity of 68.6 %. When combined with other lab parameters such as the increased CRP and lymphopenia, the specificity rises up to 78.6 %.
Conclusion:Our study shows that eosinopenia as an independent variable, is a reliable marker to differentiate COVID-19 suspect patients from other flu-like illnesses on outpatient basis, however when combined with other parameters like lymphopenia and CRP the specificity increases further.
Xia, Z.Eosinopenia as an early diagnostic marker of COVID-19 at the time of the epidemic. E Clinical Medicine. 2020;23:100398.
Lia, Q., Dinga, X.,Xiab, G.,Chend,H.G., Chena, F.,Geng,Z.Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study. E Clinical Medicine. 2020; 23:100375.
World Health Organization. Rolling updates on corona virus disease (COVID-19) (Updated18April2020). https://www.who.int/emergencies/diseases/novel-coro-navirus-2019/events-as-they-happen.AccessedApr21,2020
World Health Organization. Corona virus disease 2019 (COVID-19) situation report_74. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200403-sitrep-74-covid-19-mp.pdf?sfvrsn=4e043d03_10.AccessedApr4,2020
Djangang, N.N., Peluso, L., Talamonti, M., Izzi, A., Gevenois,P.A., Garuf,A.,et al.,Eosinopenia in COVID-19 patients: A retrospective analysis. Microorganisms. 2020;8:1929.
Tanni, F., Akker, E., Zaman, M.M., Figueroa, N., Tharian, B., Hupart, K.H. Eosinopenia and COVID-19. The Journal of the American Osteopathic Association.2020. 120:504-508.
Chusid, M.J. Eosinophils: friends or foes? The journal of allergy and clinical immunology. Practice. 2018; 6:1439-1444.
Vasiliki, E.G., Nikolaos, G., Christos, D., Serena, V., Dimitrios, D., Evangelos, D., et al., The impact of peripheral eosinophil counts and eosinophil to lymphocyte ratio (ELR) in the clinical course of COVID-19 patients: A retrospective study. In Vivo. 2021; 35(1): 641-648.
Haider, S.D. Eosinophil count as the predictor of main outcomes of COVID 19: case-control study. European Journal of Molecular & Clinical Medicine. 2020; 7(2):4429.
Soni,M. Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection. International Journal of Laboratory Hematology. 2020;00:1-5.
Outh, R., Boutin, C., Gueudet, P., Suzuki,M., Saada, M., Auma?tre,H., et al.,Eosinopenia <100/mL as a marker of active COVID-19: An observational prospective study.Journal of Microbiology, Immunology and Infection. 2021; 54; 61-68.
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.